Pluristem Therapeutics Given New $3.00 Price Target at Jefferies Group (PSTI)

Share on StockTwits

Pluristem Therapeutics (NASDAQ: PSTI) had its target price decreased by Jefferies Group from $3.50 to $3.00 in a research note released on Wednesday morning, StockRatingsNetwork.com reports. They currently have a hold rating on the stock.

“On 6/4/13, PSTI announced FDA has placed its Phase 2 for lead stem-cell product candidate PLX-PAD on clinical hold in light of a single episode of serious allergic reaction, creating further uncertainty regarding the timing of Phase 3 initiation (by ~YE13 previously). FDA will issue formal letter with questions and requests for information within the next month.,” the firm’s analyst wrote.

Shares of Pluristem Therapeutics (NASDAQ: PSTI) traded down 1.00% during mid-day trading on Wednesday, hitting $2.96. Pluristem Therapeutics has a one year low of $2.26 and a one year high of $5.00. The stock’s 50-day moving average is currently $3.09. The company’s market cap is $173.6 million.

A number of other firms have also recently commented on PSTI. Analysts at Maxim Group downgraded shares of Pluristem Therapeutics from a buy rating to a hold rating in a research note to investors on Tuesday. Analysts at MLV Capital initiated coverage on shares of Pluristem Therapeutics in a research note to investors on Friday, May 31st. They set a buy rating and a $4.50 price target on the stock.

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.

Latest News

Lackluster Data from Factories Hits Stocks
Lackluster Data from Factories Hits Stocks
Another Hack on a Payment Card System
Another Hack on a Payment Card System
Private Social Network Ello Generating Buzz
Private Social Network Ello Generating Buzz
Data Breaches at Record Highs for 2014
Data Breaches at Record Highs for 2014
Activist Investor Insists Yahoo Buy AOL
Activist Investor Insists Yahoo Buy AOL
Nike Profit Driven by Higher Margins and Demand Across Europe
Nike Profit Driven by Higher Margins and Demand Across Europe


Leave a Reply

 
 
© 2006-2014 Ticker Report. Google+.